The Medical Letter on Drugs and Therapeutics
Intravenous Diclofenac (Dyloject)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Dyloject (Hospira), an IV formulation of the NSAID diclofenac sodium, for use in adults. It can be administered alone for treatment of mild to moderate pain or in combination with opioid analgesics for moderate to severe pain. Dyloject is the first injectable formulation of diclofenac to become available in the US.

NONOPIOIDS FOR PAIN — Use of an NSAID in addition to an opioid analgesic for management of postoperative pain has been shown to reduce opioid use and the incidence of opioid-related adverse effects.1 Administration of an oral drug may not be possible during or immediately after surgery. Injectable formulations of ketorolac and ibuprofen (Caldolor)2 are approved for treatment of pain; IV ibuprofen must be infused over 30 minutes. Use of ketorolac is limited to 5 days because of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Intravenous Diclofenac (Dyloject)
Article code: 1484b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian